Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 501 - 525 of 9223 in total

Deflazacort

Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dystrophin gene, which...
Approved
Investigational
Matched Description: … [L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of ... weakness and progressive breathing and cardiovascular disability, severely impacting patient quality of ... [A179449] Deflazacort delays the onset of muscle related complications resulting from DMD[A179455] …
Matched Products: … FLANTADIN 30 MG TABLET, 10 ADET …

Beroctocog alfa

Approved
Investigational
Matched Products: … KOATE-DVI 1000 IU/10 ML IV ENJEKSİYON İÇİN LİYOFİLZE TOZ İÇEREN FLAKON …

Rufinamide

Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy. Clinical trials suggest its efficacy in the treatment of partial seizures.
Approved
Matched Description: … Clinical trials suggest its efficacy in the treatment of partial seizures. ... derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of …

Armodafinil

Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists...
Approved
Investigational
Matched Description: … Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. ... Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated ... (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. …
Matched Categories: … Metabolic Side Effects of Drugs and Substances …

Dapsone

A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of...
Approved
Investigational
Matched Description: … Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of ... It is also used with pyrimethamine in the treatment of malaria. ... A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium …
Matched Categories: … Drugs for Treatment of Lepra …

Estazolam

A benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than diazepam or nitrazepam.
Approved
Illicit
Matched Iupac: … 12-chloro-9-phenyl-2,4,5,8-tetraazatricyclo[8.4.0.0^{2,6}]tetradeca-1(10),3,5,8,11,13-hexaene …

Sacituzumab govitecan

Metastatic triple-negative breast cancer (mTNBC) is an aggressive form of breast cancer with limited treatment options involving cytotoxic chemotherapy agents. Targeted chemotherapy through the application of antibody-conjugated agents (ADCs) is a recent advance in cancer treatment. One such ADC is sacituzumab govitecan, which combines a humanized anti-trophoblast cell-surface antigen 2...
Approved
Investigational
Matched Description: … Metastatic triple-negative breast cancer (mTNBC) is an aggressive form of breast cancer with limited ... [A193653] Targeted chemotherapy through the application of antibody-conjugated agents (ADCs) is a recent ... Trodelvy™ by Immunomedics, Inc.; it is currently indicated under accelerated approval for the treatment of …

Baricitinib

Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses. Baricitinib was...
Approved
Investigational
Matched Description: … baricitinib for the treatment of COVID-19 in May 2022. ... By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune ... Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of …

Guanfacine

Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974. Guanfacine was granted FDA approval on 27 October 1986.
Approved
Investigational
Matched Description: … ,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of ... hypertension[L11274] but is now indicated as an extended release tablet for the treatment of ADHD. …

Mobocertinib

Mobocertinib is a kinase inhibitor targeted against human epidermal growth factor receptor (EGFR). It is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion mutations in the EGFR gene, which are typically associated with a poorer prognosis (as compared to "classical" EGFR mutants...
Approved
Investigational
Matched Description: … exerting an inhibitory effect on _EGFR_ exon 20 insertion mutant variants at concentrations 1.5- to 10 ... It is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion ... [A238828] Mobocertinib appears to be an effective means of treating this otherwise treatment-resistant …

Diamorphine

Diamorphine (heroin) is a narcotic analgesic that may be habit-forming. It is a controlled substance (opium derivative) listed in the U.S. Code of Federal Regulations, Title 21 Parts 329.1, 1308.11 (1987). Sale is forbidden in the United States by Federal statute. (Merck Index, 11th ed) Internationally, diamorphine is controlled under...
Approved
Illicit
Investigational
Matched Iupac: … (1S,5R,13R,14S,17R)-10-(acetyloxy)-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca …
Matched Description: … Code of Federal Regulations, Title 21 Parts 329.1, 1308.11 (1987). ... (Merck Index, 11th ed) Internationally, diamorphine is controlled under Schedules I and IV of the Single …

Wormwood

Wormwood is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Approved
Experimental

Histrelin

Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-controlled, hydrogel polymer reservoirs containing histrelin acetate that...
Approved
Withdrawn
Matched Description: … [L41715] Vantas was later discontinued by Endo Pharmaceuticals Inc. on September 21, 2021. ... This drug is a synthetic analog of naturally occurring GnRH with a higher potency. ... (CPP) due to their capacity to reduce LH levels and the concentration of sex steroids. …

Alclofenac

Alclofenac is a non-steroidal anti-inflammatory drug. It was withdrawn from the market in the United Kingdom in 1979.
Approved
Withdrawn
Matched Iupac: … 2-[3-chloro-4-(prop-2-en-1-yloxy)phenyl]acetic acid …

Ertugliflozin

Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018.
Approved
Investigational

Dostarlimab

Dostarlimab is an IgG4 humanized monoclonal antibody targeted against the human programmed death receptor-1 (PD-1). PD-1 receptors are found on T-cells and, when activated, serve to inhibit immune responses - some cancers leverage this system by overexpressing PD-1 ligands, thereby effectively inhibiting the anti-tumor immune response that would typically attempt...
Approved
Investigational
Matched Description: … [L33340] This indication was granted full FDA approval on February 10, 2023. ... cancers, including those of the skin, lung, kidneys, and liver. ... [L45161] Dostarlimab-gxly was granted second accelerated approval for the treatment of solid tumours …

Equine Botulinum Neurotoxin E Immune FAB2

Equine Botulinum Neurotoxin E Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype E. It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes E in...
Approved
Experimental
Investigational
Matched Description: … Equine Botulinum Neurotoxin E Immune FAB2 is composed of a mixture of immune globulin fragments purified ... from plasma of horses that were previously immunized with botulinum toxin serotype E. ... It is intravenously administered for the treatment of symptomatic botulism following documented or suspected …

Equine Botulinum Neurotoxin C Immune FAB2

Equine Botulinum Neurotoxin C Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype C. It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes C in...
Approved
Experimental
Investigational
Matched Description: … Equine Botulinum Neurotoxin C Immune FAB2 is composed of a mixture of immune globulin fragments purified ... from plasma of horses that were previously immunized with botulinum toxin serotype C. ... It is intravenously administered for the treatment of symptomatic botulism following documented or suspected …

Safinamide

Safinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.
Approved
Investigational
Matched Description: … Safinamide is for the treatment of parkinson's disease. ... It was approved in Europe in February 2015, and in the United States on March 21, 2017. …
Matched Categories: … Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome …

Fluorometholone

A glucocorticoid employed, usually as eye drops, in the treatment of allergic and inflammatory conditions of the eye. It has also been used topically in the treatment of various skin disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p732)
Approved
Investigational
Matched Description: … of the eye. ... It has also been used topically in the treatment of various skin disorders. ... A glucocorticoid employed, usually as eye drops, in the treatment of allergic and inflammatory conditions …
Matched Categories: … Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use …

Pentastarch

Pentastarch is an artificial colloid (hydroxyethyl starch derivative). Pentastarch is characterized by presenting five hydroxyethyl groups, which signifies an approximate 50% hydroxyethylation. It is sold under the name Pentaspan by Bristol-Myers Squibb and is used for fluid resuscitation. When administered, pentastarch remains mainly in the circulatory system and hence, it...
Approved
Investigational

Ginkgo biloba

Ginkgo biloba extract contains a group of terpene lactones (notably, ginkgolides and diterpenes) and ginkgo flavone glycosides (notably, ginkgetin, bilobetin, and sciadopitysin) that have antioxidant and vasoactive properties. Most of the studies that investigate the effect of ginkgo biloba use the standardized extract of Ginkgo biloba (EGb) 761 (EGb761), which...
Approved
Investigational
Nutraceutical
Matched Description: … [A232389] Most of the studies that investigate the effect of _ginkgo biloba_ use the standardized extract ... _Ginkgo biloba_ extract contains a group of terpene lactones (notably, ginkgolides and diterpenes) and ... of _Ginkgo biloba_ (EGb) 761 (EGb761), which was developed by a German pharmaceutical company in 1964 …
Matched Mixtures name: … DOMINGO 10/10/80 MG EFERVESAN TABLET, 30 ADET ... DOMINGO 10/10/80 MG EFERVESAN TABLET, 90 ADET ... DOMINGO 10/20/80 MG EFERVESAN TABLET, 30 ADET …

Sparsentan

Sparsentan is a dual antagonist of the endothelin type A receptor (ETAR) and the angiotensin II (Ang II) type 1 receptor (AT1R) with a similar affinity for both (9.3 nM for ETAR and 0.8 nM for AT1R).[A257330,L45300] Sparsentan is first in its class and orally active, and was created by...
Approved
Investigational
Matched Iupac: … 4'-({2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl}methyl)-N-(4,5-dimethyl-1,2-oxazol-3-yl)-2'-(ethoxymethyl …
Matched Description: … approval based on reduction of proteinuria. ... Sparsentan is a dual antagonist of the endothelin type A receptor (ETAR) and the angiotensin ... [L45315] The use of sparsentan may cause hepatotoxicity and embryo-fetal toxicity.[L45300] …

Linagliptin

Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding . Linagliptin was approved by...
Approved
Matched Description: … Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes …
Matched Mixtures name: … กลีแซมบี 10 มก./5 มก. ... GLYXAMBI® 10 MG/ 5 MG ... GLYXAMBI® 10 MG/ 5 MG …

Thiosulfuric acid

Thiosulfuric acid is available in its salt forms sodium thiosulfate and sodium thiosulfate pentahydrate. Sodium thiosulfate is part of the World Health Organization’s list of essential medicines, and it has a variety of industrial uses, including food preservative, water de-chlorinator and paper pulp bleaching agent. Sodium thiosulfate is rapidly degraded...
Approved
Investigational
Matched Description: … Sodium thiosulfate is part of the World Health Organization’s list of essential medicines, and it has ... Sodium thiosulfate is also used to reduce the risk of ototoxicity associated with [cisplatin]. ... ] and it is frequently used in conjunction with sodium nitrite (a salt form of [nitrous acid]). …
Displaying drugs 501 - 525 of 9223 in total